Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “PrimeVax Immuno-Oncology”

10 pharma patents match "PrimeVax Immuno-Oncology" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 10
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 10 pharmaceutical patents matching "PrimeVax Immuno-Oncology" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

10 results for “PrimeVax Immuno-Oncology” · 30,257 patents in full index Clear search

  1. US 12377115

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12059443

    Method for treating cancer using dengue virus serotype 1 (DENV-1)

    PrimeVax Immuno-Oncology · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  3. US 11357795

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  4. US 10946080

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted
  5. US 10765727

    Compositions and methods for producing dendritic cells

    PrimeVax Immuno-Oncology · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted
  6. US 10675304

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  7. US 10357553

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  8. US 10159727

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted
  9. US 9849167

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted
  10. US 9730989

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted